
PALISADE BIO, INC.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Palisade Bio is a clinical-stage biopharmaceutical company developing therapies for gastrointestinal diseases, including treatments aimed at conditions such as postoperative ileus and other inflammatory or fibrotic gut disorders.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Williams Donald AllenDirector | Buy | $14K | 10,000at $1.42 | Oct 1, 2026 |
| Williams Donald AllenDirector | Buy | $15K | 10,000at $1.46 | Oct 2, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PALI activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.